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Abstract 
Background: Malaria remains a significant public health issue in Eastern Indonesia, where multidrug resistant Plas-
modium falciparum and Plasmodium vivax are highly prevalent. The objective of this study was to describe treatment-
seeking behaviour and household costs prior to a change to a unified treatment policy of dihydroartemisinin-pipe-
raquine in Mimika district, Papua province in 2006.
Methods: In 2005 a randomized cross-sectional household survey was conducted to collect data on demographics, 
socio-economic status (SES), treatment-seeking, case management, and household costs. Information on the cost of 
illness was also collected from patients exiting health facilities, in order to compare the cost of episodes diagnosed as 
P. vivax compared with those diagnosed as P. falciparum.
Results: 825 households were included in the survey. Of the 764 individuals who sought treatment for fever outside 
the home in the last month, 46% (349/764) went to a public health facility. Of the 894 reported visits to healthcare 
providers, 48% (433) resulted in a blood test, of which 78% (337) were reportedly positive. Only 10% (17/177) of 
individuals who reported testing positive for P. falciparum or mixed infection received the first-line treatment of chlo-
roquine with SP, and 38% (61/159) of those with a diagnosis of P. vivax reportedly received the first-line treatment of 
chloroquine and primaquine. Overall, public facilities were more likely to prescribe the correct prevailing first-line drug 
combinations than private providers (OR = 3.77 [95% CI 2.31–6.14], p < 0.001). The mean cost to the household of an 
episode of P. vivax was similar to the cost of P. falciparum [US$44.50 (SD: 46.23) vs US$48.58 (SD: 64.65)].
Conclusions: Private providers were a popular source of treatment for malaria, but adherence to the national 
guidelines was low and the economic burden of malaria for both P. falciparum and P. vivax infections was substantial. 
Engagement with the private sector is needed to ensure that patients have access to affordable good quality, effec-
tive diagnostics and anti-malarials for both P. falciparum and P. vivax.
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Background
Great progress has been made in reducing the burden of 
malaria in the Asia Pacific region, however the ultimate 
goal of eliminating malaria has been undermined by the 
emergence and spread of drug resistance. The World 
Health Organization recommends that once anti-malar-
ial efficacy falls below 90%, treatment policy should be 
changed with a combination therapy with greater than 
95% efficacy [1].
The impact of any anti-malarial drug policy will depend 
on how it is implemented, and whether it ensures that 
individuals with malaria can easily access and receive 
the right treatment and diagnostics at an affordable cost. 
Early diagnosis of individuals with malaria and adminis-
tration of effective treatment is critical to both to indi-
vidual patients in ensuring rapid resolution of symptoms 
and preventing progression to severe disease, but also the 
community, by reducing further transmission and spread 
of anti-malarial drug resistance.
In many malaria-endemic countries, the private sec-
tor is an important source of care for individuals seeking 
treatment for malaria and most of the spending is out-of-
pocket. The private sector comprises a diverse range of 
providers including private hospitals, registered pharma-
cies and unlicensed drug shops. Having an understand-
ing of the role of different types of health care providers 
and engaging with them appropriately is, therefore, very 
important if changes in policy are to result in actual 
change in how patients with malaria are treated. Treat-
ment-seeking behaviour of patients with symptomatic 
malaria is influenced by socio-economic factors, knowl-
edge and beliefs, and access to healthcare provision. 
Malaria disproportionately affects rural poor households 
for whom one episode of illness can have catastrophic 
results, not only in terms of morbidity and mortality but 
also in terms of financial burden.
The literature on treatment-seeking behaviour for 
malaria, has shown that individuals often begin by taking 
treatment at home or from traditional healers and then 
move on to private drug sellers with few accessing pub-
lic facilities directly [2, 3]. In sub-Saharan Africa, which 
carries the highest burden of malaria, studies have shown 
that less than 25% of the private providers have malaria 
tests available [4, 5]. In Asia, a recent household survey 
in Cambodia showed that two-thirds of individuals seek 
treatment at private providers [6]. Another survey in 
Myanmar revealed that nearly half of those who sought 
treatment did so at private providers where they were less 
likely to receive a diagnostic test for malaria and more 
likely to receive anti-malarials without a diagnosis [7].
The greatest burden of malaria in Indonesia is in the 
eastern provinces including Papua, where Plasmodium 
falciparum and Plasmodium vivax are the dominant 
species [8, 9]. Malaria outbreaks are frequent, often 
triggered by the migration of non-immune individu-
als from low to high transmission areas [10]. Prior to 
2006, the first-line treatment of uncomplicated P. fal-
ciparum malaria was chloroquine (CQ) plus sulfadox-
ine-pyrimethamine (SP) and that for patients with 
uncomplicated P. vivax was CQ with 14 days of unsuper-
vised primaquine (total dose 3.5 mg/kg over 14 days), for 
patients over 1 year of age [11]. A series of anti-malarial 
efficacy studies conducted in 2004 and 2005, documented 
high levels of resistance to both CQ and SP [12, 13].
At the time of this household survey, little data were 
available on treatment-seeking behaviour, anti-malarial 
drug use and household costs of treatment for malaria 
in Indonesia, where malaria remains a significant public 
health concern [14, 15]. A household survey in 2002–
2003 indicated that less than 1% of children under the age 
of five received an anti-malarial for fever [15]. Another 
household survey conducted in Java in 2006 showed that 
the public sector was the primary source of malaria treat-
ment for less than half of those with self-reported malaria 
[14]. Although several treatment-seeking surveys have 
been conducted in Asia [6, 7, 14, 16–22], almost no data 
exists on the associated healthcare costs for P. falciparum 
and P. vivax malaria in a co-endemic area as only one 
reported costs associated with each malarial episode with 
little detail on what these costs entailed [14].
The aim of the current study was to describe treat-
ment-seeking behaviour for fever and associated costs 
of P. vivax and P. falciparum infection in Papua, prior to 
March 2006, when policy was changed to dihydroarte-
misinin-piperaquine (a fixed dose combination therapy) 
for uncomplicated malaria due to any species of malaria. 
A subsequent household survey to determine changes in 
treatment seeking and costs was conducted in 2013 and 
will be reported separately.
Methods
Site details
The survey was conducted in Mimika Regency, south-
ern Papua, Indonesia. This district covers an area of 
21,522 km2 with approximately 130,000 people living in 
12 districts in 2004. Most of the population resides in 
Timika town and the surrounding villages. The area is 
inhabited by a variety of ethnic groups, which are broadly 
categorized as lowland Papuans, highland Papuans or 
non-Papuans. The demographics, malaria transmission 
and health services in this region have been described 
previously [8].
The area is covered with thick rain forest with both 
coastal and mountainous areas. Malaria transmis-
sion occurs throughout the year and is restricted to 
the lowland area where most of the population lives. 
Page 3 of 12Karyana et al. Malar J  (2016) 15:536 
Immigration to work at the local mine is considerable 
and has the potential both to expose non-immune indi-
viduals to malaria and to introduce malaria from other 
areas of Indonesia. There are three mosquito vectors: 
Anopheles koliensis, Anopheles farauti and Anopheles 
punctulatus. Based on the malaria surveillance data, the 
annual incidence of clinical malaria, is estimated to be 
approximately 876 episodes per 1000 people, with a slight 
predominance of P. falciparum infection (46%) compared 
to P. vivax (39%) [8].
Healthcare provision is provided free of charge at the 
hospital, 12 Government-funded Primary Health Clinics 
(Puskesmas) and, for those employed by a local mining 
company, at the malaria control clinics where parasito-
logical diagnosis by microscopy and rapid diagnostic test 
are available. There is also a thriving private sector, which 
includes clinics, pharmacies and drug stores. Whilst anti-
malarials are officially prescription drugs, they can also 
be purchased over the counter at the private sector [10]. 
The malaria surveillance programme does not capture 
the malaria cases seen in the private sector.
Household sampling strategy
The survey was conducted in the Mimika district 
between July and December 2005.
The sample size calculation aimed to estimate the true 
prevalence of households with someone with a recent 
history of fever and was based on an estimated preva-
lence of 40% and population size of 140,000; a multiplica-
tion factor of 2 was used to take into account the design 
effect due to cluster sampling. A sample size of 800 
households was required to achieve an estimate of preva-
lence with greater than 95% confidence.
A three-stage cluster sampling procedure was applied 
to identify 32 clusters of 25 households [23]. Firstly the 
four most populous sub-districts (Mimika Baru, Mimika 
Timur, Kuala Kencana and Tembaga Pura) were chosen 
from the 12 sub-districts based on their accessibility by 
road from the main town of Timika and because they 
included the majority (80%) of the district’s population. 
Secondly, the number of clusters in each sub-district was 
apportioned according to their relative populations. The 
houses were then assigned numbers according to their 
geographical location and clusters of 25 houses were 
identified randomly according to WHO guidelines with 
the first house identified by random allocation.
Members of the households were defined as all individ-
uals living under one roof, who ate from one kitchen and 
had resided in the study area for at least six months. If a 
selected household was empty, the interviewer returned 
the next day. If still unoccupied, the next occupied house-
hold was sampled instead. Temporary migrants were 
defined as individuals who had moved into the area 
within last six months and did not plan to stay longer 
than six months; these were excluded from the survey.
Data collection
The survey was conducted using a structured question-
naire capturing self-reported household demographic 
data, income, average monthly food and non-food expen-
ditures, expenditure on healthcare in the last month, 
ownership of assets, and bed net ownership and use. 
Nearly all surveys were conducted in the local language, 
Bahasa Indonesian. The survey was conducted with the 
head of the household or another suitable adult and 
details on all household members gathered. Those mem-
bers who were present were asked specific details about 
recent illness, had a physical examination and were asked 
to consent to a blood film as previously described [8].
In order to obtain detailed information about the care-
seeking process and cost of illness, individuals reporting 
a history of fever in the preceding 30 days were asked to 
complete a separate module on treatment-seeking, com-
prising of questions on all the places that they went to 
seek treatment, whether they received a blood tests and 
the type of medicines they received. They were also asked 
to about direct and indirect household costs includ-
ing the cost of treatment, transport, productivity losses 
due to illness, and companion, caretaking and substitute 
labour [21].
An exit survey was also undertaken on patients with 
confirmed malaria as they left public facilities in order 
to collect accurate information on household costs in 
relation to type (species) of malaria infection. The exit 
interviews were carried out over a period of four months 
in the hospital, two of the four Puskesmas and three of 
the eight malaria control clinics. The number of inter-
views per type of facility was proportional to the num-
ber of malaria patients each facility saw each month. Any 
patient with a parasitological diagnosis of malaria was 
eligible for inclusion. Patients completed a questionnaire 
with the aid of a research nurse to document treatment-
seeking and costs of illness. With a shorter time between 
the event and the survey, these results were less likely to 
be confounded by recall bias and enabled a greater cer-
tainty about malaria species diagnosis with the disadvan-
tage of truncating the costs at the end of the healthcare 
visit.
Data analysis
Data were analysed using STATA statistical software 
(version 14) [24] and R (version 3.2.3) [25]. Frequen-
cies and percentages were used for the descriptive data. 
Percentages were compared using the Chi square test 
(X2). Differences in outcome distributions were tested 
using Mann–Whitney test for two groups and the 
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Kruskal–Wallis H test for more than two groups. Contin-
uous variables were compared using Spearman’s rank for 
correlation. Simple logistic regression was used to calcu-
late odds ratios (ORs). The variables that were significant 
risk factors (p < 0.05) for fever in the past month in the 
univariate analysis were included in a multiple logistic 
regression model. Regression models involving behaviour 
of the individuals were adjusted for clustering by house-
holds, since more than one household member could 
have been present for each household.
For the analysis on treatment-seeking behaviour, 
those who reported that their fever started in the last 
2  days were excluded in order to ensure that only indi-
viduals who had had sufficient time to seek or not seek 
treatment were included. For those included in the 
treatment-seeking behaviour analysis the following out-
comes were calculated: the percentage that reported 
taking any medicines (including at home or traditional 
medicine) and percentage seeking treatment outside of 
the home according to the number and type of provider, 
categorised into private providers (private clinics, phar-
macies and drug shops) and public facilities (the hospital, 
Puskesmas and malaria control clinics).
In order to explore how patients were managed at 
each provider in terms of blood testing and prescrip-
tions of anti-malarials, further analysis was undertaken 
on each patient-provider interaction (“visit”). As anti-
malarial injections pose the risk of infection to patients 
and are largely inappropriate treatments for uncompli-
cated malaria, individuals were also asked whether they 
received an injection or tablets or both.
In order to categorise the surveyed by socio-economic 
status, a Discriminant Analysis of Principal Components 
[26] was used to analyse the data on reported household 
ownership of assets. This approach maximized between 
group variability while minimizing within group variabil-
ity, capturing heterogeneity in ownership that was not 
seen using a standard principal component analysis [27]. 
In order to investigate the relationship between SES and 
other outcomes captured by the survey, the groups were 
ranked from poorest to richest in terms of both income 
and expenditure per household member.
Costs were gathered in Indonesian rupiah (IDR), and 
converted into United States Dollars (US$) using the 
average exchange rate for 2005 [28] and then revised 
to the 2014 equivalent using the consumer price index 
for Indonesia [29]. To represent the cost burden on 
households, the mean and standard deviation (SD) are 
reported. As the data were skewed, the Mann–Whitney 
test was used for comparisons; the median and inter-
quartile range (IQR) are included in the Additional files. 
Direct costs, including consultation, diagnosis, medica-
tion, overnight stays, administration and transportation, 
were reported according to where treatment was 
obtained [30]. Indirect costs, including lost wages for 
companions, caretakers and substitute labourers, are 
aggregated into cost per individual taking treatment. As 
a result, when multiple companions, caretakers or sub-
stitute labourers were reported for a single individual 
taking treatment, their times were summed, resulting in 
the mean days per individual taking treatment. The mean 
wage was calculated for all who reported a wage, includ-
ing individuals taking treatment, companions, caretak-
ers and substitute labourers. This wage was applied to 
all who reported reducing their activities because they 
had a fever or were a companion, caretaker or substi-
tute labourer for someone with a fever. For those who 
reported reducing some of their usual activities, the days 
of lost activity were multiplied by one half day’s wage and 
included in the total costs.
Results
Household demographics, SES and expenditure
In total 825 households with 5255 individuals were 
included in the survey between July and December 
2005 (Fig.  1). The median household size was six indi-
viduals (IQR 4–8) with a maximum of 24 in one house. 
The median duration that a household had lived at that 
location was nine years (IQR 4–15). Thirty-four (4%) of 
households reported moving into that location less than 
a year previously. Of the 763 households in which income 
was recorded, 63% (482) reported a total monthly income 
of less than US$500.
For the SES, the Discriminant Analysis of Principal 
Components resulted in households being split into five 
groups ranging in size from 111 to 203. Richer house-
holds had electricity and owned electrical items but did 
not always own a house or land, whereas poorer house-
holds tended to own houses, land and grow crops, but 
were less likely to have electricity (Additional file  1: 
Figure S1). Household SES was significantly lower in 
Highland Papuan household with 47% (101/216) of 
Highland Papuans in the poorest categories compared 
to 12% (22/190) of Lowland Papuans and 4% (16/416) of 
non-Papuans (p < 0.001). The household general health 
expenditure in the previous month was significantly 
lower in households with lower SES (p  =  0.001; Addi-
tional file 2: Figure S2). The estimated household general 
health expenditure was correlated with the number of 
individuals reporting fever in a household (ρ  =  0.209, 
p < 0.001).
Only 340 (41%) of households reported owning a bed 
net, and this was inversely correlated with SES with 
51% (72/140) in the poorest group reported bed net 
ownership as compared to 29% (32/111) in the richest 
(p < 0.001).
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Fig. 1 Flow diagram. Diagrammatic presentation of household members, interviews, initial location of treatment taking, and whether took a 
second treatment
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History of fevers and parasite positivity of household 
members
In total 3896 (74%) of individuals were present at the 
time of interview (Fig. 1) of whom 48% (1877) were male, 
42% (1644) were under the age of 15 (Table 1), and 53% 
(2069) were Papuan. In total, 1631 (42%) of individuals 
from 700 (85%) households reported having had a febrile 
illness in the preceding month. Significant independent 
risk factors for febrile illness included age, ethnicity, and 
poor economic status (Table 2).
In those who consented to blood testing, malaria slide 
positivity was 16% (634/3890) of whom 46% (290) were 
infected with P. falciparum, 39% (248) with P. vivax, 11% 
(72) with mixed infections and 4% (24) with P. malariae. 
Individuals in the lower three SES groups were more 
likely to be parasite positive than those in the top two 
SES groups (OR = 1.33 [95% CI 1.05–1.68], p = 0.019).
Treatment‑seeking behaviour of household members
Treatment-seeking behaviour was assessed in 72% 
(1176/1631) of individuals who reported fever in the pre-
ceding month (Fig. 1). The analysis of treatment-seeking 
was restricted to the 94% (1104/1176) of individuals with 
a fever commencing at least two days before the survey 
(Fig. 1). Three-quarters (76%, 834/1104) reportedly took 
some form of medicine. For the 270 (24%) of participants 
who did not take any medication, the most common 
explanation offered was that the disease was not severe 
enough to warrant it (169, 63%).
Of those who took some form of medicine, 92% 
(764/834) sought treatment outside of the home at 
some point. Treatment-seeking outside of the home 
was significantly more likely in those who had a febrile 
illness lasting two or more days (OR  =  2.97 [95% CI 
2.15–4.09], p < 0.001), were in the richest two SES groups 
(OR  =  1.99 [95% CI 1.42–2.78], p  <  0.001) and were 
non-Papuan (OR = 2.63 [95% CI 1.92–3.60], p < 0.001). 
Treatment-seeking was not influenced by age or gender. 
Of those who sought treatment outside of the home, 46% 
(349/764) went to a public provider at least once; this 
percentage being greater in those who were female, less 
than 15 years old, Papuan ethnicity or from the poorest 
SES (Table 3).
The 764 individuals who sought treatment outside of 
the home reported a total of 894 visits to healthcare pro-
viders. Further analyses were undertaken on these 894 
interactions with providers.
Diagnosis of malaria at healthcare providers
Out of the 894 visits to health care providers, a blood 
test for malaria was reportedly undertaken in 433 (48%) 
of these visits (Table 4) of which 78% (337) were report-
edly positive: half (167) P. falciparum, 47% (159) P. vivax, 
3% (10) mixed infections and 0.3% (1) P. malariae. For 3% 
(12/433) of visits, no result was reported. Children who 
were 14 years old or younger were more likely to have a 
blood test compared to individuals over the age of 14 (OR 
1.42 [95% confidence interval (CI) 1.10–1.84], p = 0.007), 
Table 1 Demographic characteristics of individuals in surveyed households





vious month (N = 1631, 
42%)





0–4 870 (17%) 820 (21%) 405 (25%) 205 (25%)
5–14 1101 (21%) 824 (21%) 306 (19%) 148 (18%)
15+ 3284 (62%) 2252 (58%) 920 (56%) 481 (58%)
Sex (female)—n (%) 2409 (46%) 2019 (52%) 850 (52%) 433 (52%)
Pregnant (yes)—n (%) 92 (2%) 87 (2%) 39 (2%) 23 (3%)
Place of birth—n (%)
Highland Papuan 1494 (28%) 1045 (27%) 385 (24%) 172 (21%)
Lowland Papuan 1371 (26%) 1024 (26%) 463 (28%) 183 (22%)
Non-Papuan 2390 (45%) 1827 (47%) 783 (48%) 479 (57%)
Resided in lowlands for more than 
1 year? (yes)—n (%)
4969 (95%) 3674 (94%) 1547 (95%) 797 (96%)
District—n (%)
Mimika Baru 4401 (84%) 3242 (83%) 1401 (86%) 740 (89%)
Mimika Timur 371 (7%) 286 (7%) 108 (7%) 11 (1%)
Kuala Kencana 331 (6%) 249 (6%) 93 (6%) 65 (8%)
Tembaga Pura 152 (3%) 119 (3%) 29 (2%) 18 (2%)
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although they were less likely to have a detectable parasi-
taemia (OR 0.30 [95% CI 0.18–0.51], p < 0.001).
Anti‑malarial treatment at healthcare providers
An anti-malarial (alone or with other medicines) was 
reportedly prescribed during 61% (547/894) of vis-
its: 86% (471/547) of which were prescribed as tablets, 
5% (30/547) as an injection and 8% (46/547) as both an 
injection and tablets. Overall, public facilities were sig-
nificantly more likely to prescribe anti-malarial treatment 
than private providers (OR  =  1.41 [95% CI 1.07–1.86], 
p =  0.015); however, the majority (92%, 70/76) of anti-
malarial injections were administered by private clinics 
or doctors.
In relation to parasitological testing prior to anti-
malarial prescription, 61% (336/547) of the anti-malarial 
prescriptions followed a blood test. The corresponding 
figures were 87% (215/247) at public facilities and 40% 
(121/300) at private providers (p < 0.001).
Only 10% (17/177) of individuals who reported test-
ing positive for P. falciparum or mixed infection reported 
receiving the prevailing first-line treatment of chloro-
quine with SP, with the majority receiving primaquine 
(129; 73%), chloroquine (103; 58%) and/or quinine (49; 
28%). Those reporting a diagnosis of P. vivax were more 
likely to receive the correct first line treatment of chlo-
roquine and primaquine [38% (61/159); Table 5]. Overall, 
public facilities were more likely to prescribe the cor-
rect drug combinations (OR = 3.77 [95% CI 2.31–6.14], 
p < 0.001).
In total, 69% (232/337) of respondents who reported a 
positive blood test for malaria, reported being prescribed 
primaquine. Of those who reported taking primaquine 
for P. vivax infection (alone or mixed), 63% (69/109) 
reported taking less than 7 days of treatment (Fig. 2).
Direct costs of treatment‑seeking
The mean total direct cost to the household per visit at 
a private provider was US$12.46 (SD = 30.25) compared 
to US$3.52 (SD = 14.33) at the public sector (p < 0.001). 
Table  4 shows the mean cost of treatment (including 
drugs, consultation and diagnosis) and transport (includ-
ing patient and any accompanying people) by source of 
treatment; Additional file  3: Table S1 shows the corre-
sponding median treatment costs. No significant differ-
ence in direct costs were seen for those diagnosed with P. 
falciparum as compared with P. vivax infection. The total 
direct costs per person according to age group are pre-
sented in Additional file 4: Table S2.
Indirect costs per fever episode
Overall, 77% (641/834) of those who reported taking treat-
ment stated that at least one person had reduced his or 
her usual activities to care for them and 66% (553/834) of 
respondents reported having at least one companion with 
them when seeking treatment. Eight percent (66/834) of 
respondents  reported the need for at least one substitute 
labourer to perform their usual activities while sick and 
this was significantly more likely in non-Papuans compared 
to Papuans (OR = 2.09 [95% CI 1.19–3.65], p = 0.010). Of 
those who reported a daily wage, the mean was US$10.92 
(SD  =  8.22). The days lost by the individual and his/her 
companions, caretakers and substitute labourers are shown 
in Additional File 4: Table S2 along with their associated 
costs. The total mean indirect cost per fever episode requir-
ing treatment taking was US$31.49 (SD = 35.92) for chil-
dren and US$53.52 (SD = 58.06) for adults.
Table 2 Logistic regression analysis of  risk factors 
for reporting a fever in the past month (N = 3896)
The multiple logistic regression included variables that were significant 
(p < 0.05) in the univariate logistic regression
Variable OR (95% CI) p value AOR (95% CI) p value
Gender
Male Reference Reference
Female 1.02 (0.90–1.16) 0.756 – –
Age (years)




Yes 1.13 (0.74–1.73) 0.566 – –
Household size
≤7 members 1.16 (0.98–1.38) 0.091 – –
>7 members Reference Reference
SES groups
Richest Reference Reference
Fourth 1.47 (1.11–1.95) 0.007 1.47 (1.11–1.96) 0.007
Middle 1.33 (1.00–1.76) 0.050 1.40 (1.05–1.87) 0.022
Second 1.17 (0.89–1.53) 0.270 1.35 (1.01–1.80) 0.046
Poorest 1.52 (1.15–2.00) 0.003 2.04 (1.48–2.81) <0.001
Ethnicity
Highland Papuan Reference Reference
Lowland Papuan 1.41 (1.12–1.78) 0.003 1.64 (1.28–2.10) <0.001
Non-Papuan 1.29 (1.06–1.55) 0.009 1.59 (1.26–2.01) <0.001
Resided in lowlands >1 year?
No Reference Reference
Yes 1.19 (0.86–1.66) 0.292 –
Family sleeps under a bed net?
No Reference Reference
Yes 1.02 (0.86–1.21) 0.792 –
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Malaria costs from healthcare facility exit survey
A total of 358 patients were surveyed after exiting six 
public health care facilities (the hospital, 2 Puskesmas 
and 3 malaria control clinics). The reported diagnosis 
was P. falciparum in 55% (196), P. vivax in 38% (136), 
mixed infection in 4% (12), P. malariae in 4% (13) and P. 
ovale in 0.3% (1). The direct and indirect costs related to 
visits at public providers for P. falciparum and P. vivax 
are presented in Table 6 and Additional file 5: Table S3. 
The total costs were similar between the species of diag-
nosis, however respondents with P. falciparum infection 
reportedly spent more money than those with P. vivax for 
Table 3 Sociodemographic characteristics associated with whether ever sought treatment at a public provider (N = 764)
This is among fever patients who sought treatment outside of the home
OR = Odds Ratio; 95% CI = 95% confidence intervals
Variable Source of treatment [% (n)] Univariate OR (95% CI) p value
Private provider(s) only (N = 415) Public provider ever (N = 349)
Gender
Male 60% (219) 40% (148) Reference
Female 49% (196) 51% (201) 1.52 (1.14–2.02) p = 0.004
Age group (years)
<5 49% (93) 51% (98) 1.53 (1.06–2.21) p = 0.024
5–15 46% (61) 54% (71) 1.69 (1.13–2.53) p = 0.011
15+ 59% (261) 41% (180) Reference
Ethnicity
Non-Papuan 67% (288) 33% (142) Reference
Papuan 38% (127) 62% (207) 3.31 (2.31–4.73) p < 0.001
SES quintile
Poorest 31% (36) 69% (81) 7.03 (3.82–12.95) p < 0.001
Second 46% (80) 54% (95) 3.71 (2.03–6.78) p < 0.001
Middle 58% (100) 42% (73) 2.28 (1.25–4.16) p = 0.007
Fourth 59% (99) 41% (68) 2.14 (1.17–3.93) p = 0.013
Highest 76% (100) 24% (32) Reference
Table 4 Percentage of respondents who reported receiving blood tests, anti-malarials and associated costs (N = 894)
Mean cost and standard deviation (SD) by type of healthcare provider are reported in US$. Visit costs includes costs of consultation, diagnosis, medications and any 
other costs directly related to the care received. Transport cost includes costs for the patient and anyone who accompanied him or her
a OR = 7.94 [95% CI 5.86–10.76]
b OR = 1.41 [95% CI 1.07–1.86]
c Mann–Whitney test
† Government-funded primary health clinic
†† Mining company-funded clinic
Healthcare provider Percentage with blood test 
for malaria n (%)
Frequency anti‑malarials 
were prescribed n (%)
Visit costs Transport costs Total direct costs
Mean (SD) Mean (SD) Mean (SD)
Private (N = 519) 148 (29%) 300 (58%) 11.52 (29.86) 0.93 (1.96) 12.46 (30.25)
Private clinic or doctor 
(N = 240)
124 (52%) 187 (78%) 21.66 (41.44) 1.53 (2.73) 23.19 (41.77)
Pharmacy (N = 173) 23 (13%) 87 (50%) 3.76 (5.26) 0.58 (0.39) 4.34 (5.29)
Shop (N = 106) 1 (1%) 26 (25%) 1.25 (1.44) 0.15 (0.32) 1.40 (1.57)
Public (N = 375) 285 (76%) 247 (66%) 2.63 (13.87) 0.88 (1.66) 3.52 (14.33)
Puskesmas (N = 155)† 102 (66%) 94 (61%) 3.40 (11.20) 0.57 (0.69) 3.97 (11.57)
Malaria control clinic 
(N = 149)††
123 (83%) 107 (72%) 0.00 (0.00) 0.57 (1.59) 0.57 (1.59)
Hospital (N = 71) 60 (85%) 46 (65%) 6.49 (26.86) 2.24 (2.46) 8.72 (27.41)
p value (private vs public) <0.001a 0.015b <0.001c 0.080c <0.001c
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the healthcare visit (p = 0.013), personal transportation 
to the healthcare facility (p  <  0.001) and lost wages for 
the patient (p =  0.001). Individuals with P. vivax infec-
tion spent more money on companion costs (p = 0.034). 
When the analysis was restricted to children or adults, 
the only cost that remained statistically significant was 
for the healthcare visit.
Discussion
This study from Papua, Indonesia, was conducted in an 
area with one of the greatest levels of malaria burden in 
the region and at a time of high levels of anti-malarial 
drug resistance to prevailing first-line therapies. It is the 
first study from eastern Indonesia reporting household 
treatment-seeking behaviour and is one of the few stud-
ies comparing household costs of P. vivax malaria with P. 
falciparum malaria, as well as self-reported adherence to 
14 day primaquine.
There were several significant findings of relevance to 
malaria control efforts. Firstly in relation to treatment 
seeking, almost a third of individuals reporting a fever 
in the last month did not seek treatment outside of the 
home. This figure is higher than previous reports from 
central Java where 88% of households reported seeking 
treatment or advice outside of the home for their most 
recent malaria illness [14]. Over half (54%) of individu-
als sought treatment only in the private sector, despite 
the availability of free treatment in the public sector. 
Table 5 Anti-malarial treatment received according to blood test results as reported in the household survey
a Includes tablets and injections
b Medication categories are not mutually exclusive
† Government-funded primary health clinic
†† Mining company-funded clinic
* Recommended treatment regimen
Private clinic or 
doctor
Pharmacy Shop All private Puskesmas† Malaria control 
clinic††
Hospital All public Overall
Not tested (N) 116 150 105 371 53 26 11 90 461
% (n) anti-malarialsa 69% (80) 49% (73) 25% (26) 48% (179) 43% (23) 35% (9) 0% (0) 36% (32) 46% (211)
Tested negative (N) 16 5 1 22 28 21 13 62 84
% (n) anti-malarialsa 19% (3) 0% (0) 0% (0) 14% (3) 0% (0) 5% (1) 0% (0) 2% (1) 5% (4)
P. falciparum (N) 57 11 0 68 29 50 20 99 167
% (n) anti-malarialsab 98% (56) 73% (8) – 94% (64) 97% (28) 100% (50) 95% (19) 98% (97) 96% (161)
% (n) CQ*b 51% (29) 27% (3) – 47% (32) 79% (23) 88% (44) 5% (1) 69% (68) 60% (100)
% (n) SP*b 5 (9%) 0% (0) – 7% (5) 0% (0) 28% (14) 0% (0) 14% (14) 11% (19)
% (n) PQb 68% (39) 27% (3) – 62% (42) 83% (24) 92% (46) 55% (11) 82% (81) 74% (123)
% (n) quinineb 33% (19) 36% (4) – 34% (23) 17% (5) 6% (3) 75% (15) 23% (23) 28% (46)
% (n) anti-malarial 
injectionb
32% (18) 9% (1) – 28% (19) 3% (1) 0% (0) 10% (2) 3% (3) 13% (22)
P. vivax (N) 44 7 0 51 41 43 24 108 159
% (n) anti-malarialsab 95% (42) 86% (6) – 94% (48) 100% (41) 98% (42) 100% (24) 99% (107) 97% (155)
% (n) CQ*b 34% (15) 71% (5) – 39% (20) 68% (28) 77% (33) 8% (2) 58% (63) 52% (83)
% (n) PQ*b 34% (15) 0% (0) – 29% (15) 78% (32) 81% (35) 88% (21) 81% (88) 65% (103)
% (n) quinineb 34% (15) 14% (1) – 31% (16) 24% (10) 5% (2) 88% (21) 31% (33) 31% (49)
% (n) anti-malarial 
injectionb
11% (5) 0% (0) – 10% (5) 0% (0) 0% (0) 4% (1) 1% (1) 4% (6)
Fig. 2 Histogram of primaquine treatment. Reported number of 
days of primaquine treatment for P. falciparum and P. vivax/mixed 
infections (n,%)
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Those who sought care in the private sector were less 
likely to report a diagnosis of malaria, but almost 60% 
still reported receiving anti-malarial treatment. Fifteen 
percent of individuals with fever reported more than 
one source of treatment, a likely consequence of the ini-
tial treatment failing to improve their symptoms. These 
findings highlight the importance of engaging with pri-
vate sector in malaria control efforts and of the need to 
understand and address the reasons underling patient’s 
preferences.
Secondly in relation to anti-malarial treatment, of those 
patients who reported positive blood tests for malaria, 
few were prescribed the recommended drug regimen for 
the species that they reported; and for patients reporting 
P. vivax infections who reportedly received primaquine, 
over half of participants reported taking less than three 
days of the recommended 14  day regimen, a duration 
ineffective in preventing relapse [31].
Furthermore, primaquine was not recommended 
for P. falciparum, but the majority of patients reported 
receiving it. With such a large proportion of P. falcipa-
rum patients reporting primaquine use, it seems unlikely 
that this is entirely due to patient recall bias in terms of 
the species diagnosed or the drug prescribed. Such dis-
crepancies in anti-malarial policy and actual practice 
have been described previously in other settings [32, 33]. 
There are many possible reasons including lack of pro-
vider awareness or understanding, patient and provider 
preferences, perceptions and experiences with regards 
efficacy and side effects. Understanding and addressing 
the reasons for these discrepancies is clearly important, 
especially in the face of increasing anti-malarial drug 
resistance.
Thirdly in relation to household costs, the household 
financial burden of fevers in this region was substantial 
and did not differ substantially by the species of malaria. 
The mean cost per fever episode reported in the house-
hold survey was (US$53.54) and included the direct costs 
of the whole illness episode, including subsequent visits 
to treatment providers, as well as any further indirect 
costs of time incurred after visits to a healthcare facility. 
The mean cost of visiting a public provider for P. vivax 
malaria was US$44.50, compared to US$48.58 for P. falci-
parum. This likely represents an underestimate of house-
hold costs as patients were at public facilities and not at 
the end of their malaria episode.
Over 60% of households reported a monthly income 
less than $500, indicating that a fever episode repre-
sented at least 11% of the household’s monthly income. 
This also represents nearly 5  h of work using the 
mean reported hourly wage of US$10.92. Individu-
als in poorer households were at greater risk of fevers, 
with additional indirect costs likely to accumulate 
in those who do not take effective treatment. These 
findings emphasize the enormous economic burden 
of recurrent P. vivax episodes on the most vulnerable 
communities.
Another strength of this study, is the use of Discri-
minant Analysis of Principal Components to create 
meaningful SES categories. In this setting, use of the 
traditional asset index would have resulted in misclas-
sification of households into categories which would 
have not reflected a useful categorization of house-
hold’s actual status. Re-settled Papuans had been pro-
vided with house and land by the local government 
resulting in many of the poorer households having high 
Table 6 Patient costs per visit in US$ from facility exit surveys, mean (standard deviation)
Visits were to public providers only and reported by malaria diagnosis
The per day wage was taken from the household survey (US$10.93). Mixed infections are excluded
Italic values indicate significance of p value (p < 0.05)
a For children, lost wages are recorded as no cost
P. falciparum (n = 196) P. vivax (n = 136) p value
Total direct costs 2.69 (4.67) 2.09 (3.35) 0.056
Visit cost 0.90 (3.08) 0.40 (0.53) 0.013
Transport cost for patient 0.61 (1.41) 0.40 (1.24) <0.001
Transport cost for companions 1.18 (2.53) 1.28 (2.61) 0.541
Total indirect costs 45.90 (63.10) 42.41 (44.98) 0.960
Lost wages for patienta 17.23 (29.73) 8.79 (19.59) 0.001
Lost wages for companions 5.46 (7.28) 6.95 (7.33) 0.034
Lost wages for caretakers 22.04 (40.55) 26.51 (36.39) 0.089
Lost wages for substitute labourers 1.25 (6.85) 0.16 (1.87) 0.096
Total costs 48.58 (64.65) 44.50 (46.23) 0.981
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levels of house and land ownership but little other dis-
posable income. Lower SES status was a risk factor for 
both recent febrile illness and parasite positivity at the 
time of the survey. Those with lower SES status were 
more likely to ever seek treatment at a public facility, a 
likely reflection of the lower costs incurred. This, along 
with the higher likelihood of reporting fever in the past 
month by those with lower SES, highlights the hetero-
geneity of the population in relation to risk of fever and 
treatment-seeking behaviour.
This study has a number of limitations. Firstly, many 
of the older male household members were not present 
at the time of the survey and therefore not included in 
the analysis. In this region it is often the adult males 
who are at higher risk of malaria and so it is possible 
that we underestimated the true burden of fever epi-
sodes. Furthermore, males were more likely than females 
to seek treatment at private providers, which would 
have impacted the overall results with regards to treat-
ment-seeking behaviour and costs [8]. Another group 
excluded from the survey were temporary migrants who 
had moved into the area within last six months and did 
not plan to stay longer than six months. Depending on 
where they moved from, these individuals might be more 
susceptible to malaria than the general population. The 
survey was also undertaken in the 4 most accessible and 
populous sub-districts whose population may not be rep-
resentative of the those in the more remote sub-districts 
where access to health care is more difficult; therefore, 
results may slightly overestimate the proportion seeking 
treatment outside the home.
A common issue with all surveys aimed at describing 
treatment-seeking behaviour and case management for 
malaria, is the unknown malaria status of the individuals 
who reported having a fever in the past month. Includ-
ing all fevers in the previous month, enables the potential 
capture of entire fever episodes; however, they may also 
result in significant recall bias due to the length of time 
between the episode and the survey. In order to trian-
gulate these results, healthcare facility exit surveys were 
undertaken in which patients were interviewed imme-
diately after their visit, thus minimizing the potential 
for bias and enabling an examination of costs specific to 
the type of malaria diagnosed. Any treatment or indirect 
costs occurring other than this healthcare visit, however, 
would not be captured by this survey and thus potentially 
impact its cost estimates.
This study was undertaken at a time of very high treat-
ment failure to the recommended first-line anti-malarials 
[11]. The poor efficacy of available treatments may partly 
explain the high rates of reported fever in the preceding 
month and why a third of respondents did not access 
treatment outside of the home.
Conclusions
In summary these findings highlight a high level of 
reported febrile illness, which is most apparent in young 
children and those from poor households. Despite the 
provision of free treatment in public health facilities, 
treatment-seeking in the private sector was higher than 
expected, with considerably higher costs. The household 
costs of P. vivax were similar to P. falciparum, and in view 
of the relapsing and recurrent nature of malaria in this 
location, the financial burden of both infections is likely 
to be considerable. Anti-malarial programmes imple-
menting policy change of first-line treatment will need to 
engage both public and private sectors if early diagnosis 
and highly effective treatment is to impact on the whole 
community.
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